IQVIA Holdings Inc. stock falls 2.97% and ends two-day winning streak

11 articles · Updated · MarketWatch · Apr 28

Shares closed at $158.98 on Tuesday, underperforming the S&P 500 and Dow Jones amid a broad market decline.
IQVIA's stock is now 35.65% below its 52-week high of $247.05 reached on January 9th, with trading volume at 1.4 million, below its 50-day average.
The stock's performance was mixed compared to competitors, with HCA Healthcare falling 3.11%, Centene rising 13.95%, and Labcorp dropping 1.47% during the session.

As Centene soars on strong results, can IQVIA's earnings report prevent it from falling further behind peers?

Why do analysts rate IQVIA a 'Buy' despite its stock trading 35% below its high?

Is IQVIA's weak liquidity a major risk, or will its record backlog ensure stability through market uncertainty?

Can IQVIA's new AI tools deliver real cost savings to pharma clients who are now cutting spending?

With AI reshaping drug discovery, is IQVIA's acquisition strategy aggressive enough to maintain its market leadership?

Does IQVIA's massive patient data collection for AI create an unbeatable advantage or a significant ethical risk?